<?xml version='1.0' encoding='utf-8'?>
<document id="28680834"><sentence text="Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction." /><sentence text="Chronic hepatitis C virus (HCV) infection is a leading cause of chronic liver disease" /><sentence text=" The introduction of direct acting antiviral agents (DAAs) for its treatment represents a major advance in terms of sustained virologic response (SVR) rates and adverse effect profiles" /><sentence text=" Mechanistically, DAAs inhibit specific HCV non-structural proteins (NS) that are vital for its replication" /><sentence text=" Boceprevir, telaprevir, simeprevir, asunaprevir, grazoprevir and paritaprevir are NS3/4A inhibitors"><entity charOffset="1-11" id="DDI-PubMed.28680834.s5.e0" text="Boceprevir" /><entity charOffset="13-23" id="DDI-PubMed.28680834.s5.e1" text="telaprevir" /><entity charOffset="25-35" id="DDI-PubMed.28680834.s5.e2" text="simeprevir" /><entity charOffset="37-48" id="DDI-PubMed.28680834.s5.e3" text="asunaprevir" /><entity charOffset="50-61" id="DDI-PubMed.28680834.s5.e4" text="grazoprevir" /><entity charOffset="66-78" id="DDI-PubMed.28680834.s5.e5" text="paritaprevir" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e0" e2="DDI-PubMed.28680834.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e0" e2="DDI-PubMed.28680834.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e0" e2="DDI-PubMed.28680834.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e0" e2="DDI-PubMed.28680834.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e0" e2="DDI-PubMed.28680834.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e0" e2="DDI-PubMed.28680834.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e1" e2="DDI-PubMed.28680834.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e1" e2="DDI-PubMed.28680834.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e1" e2="DDI-PubMed.28680834.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e1" e2="DDI-PubMed.28680834.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e1" e2="DDI-PubMed.28680834.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e2" e2="DDI-PubMed.28680834.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e2" e2="DDI-PubMed.28680834.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e2" e2="DDI-PubMed.28680834.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e2" e2="DDI-PubMed.28680834.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e3" e2="DDI-PubMed.28680834.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e3" e2="DDI-PubMed.28680834.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e3" e2="DDI-PubMed.28680834.s5.e5" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e4" e2="DDI-PubMed.28680834.s5.e4" /><pair ddi="false" e1="DDI-PubMed.28680834.s5.e4" e2="DDI-PubMed.28680834.s5.e5" /></sentence><sentence text=" Ombitasvir, ledipasvir, daclatasvir, elbasvir and velpatasvir are NS5A inhibitors"><entity charOffset="1-11" id="DDI-PubMed.28680834.s6.e0" text="Ombitasvir" /><entity charOffset="13-23" id="DDI-PubMed.28680834.s6.e1" text="ledipasvir" /><entity charOffset="25-36" id="DDI-PubMed.28680834.s6.e2" text="daclatasvir" /><entity charOffset="38-46" id="DDI-PubMed.28680834.s6.e3" text="elbasvir" /><entity charOffset="51-62" id="DDI-PubMed.28680834.s6.e4" text="velpatasvir" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e0" e2="DDI-PubMed.28680834.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e0" e2="DDI-PubMed.28680834.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e0" e2="DDI-PubMed.28680834.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e0" e2="DDI-PubMed.28680834.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e0" e2="DDI-PubMed.28680834.s6.e4" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e1" e2="DDI-PubMed.28680834.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e1" e2="DDI-PubMed.28680834.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e1" e2="DDI-PubMed.28680834.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e1" e2="DDI-PubMed.28680834.s6.e4" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e2" e2="DDI-PubMed.28680834.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e2" e2="DDI-PubMed.28680834.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e2" e2="DDI-PubMed.28680834.s6.e4" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e3" e2="DDI-PubMed.28680834.s6.e3" /><pair ddi="false" e1="DDI-PubMed.28680834.s6.e3" e2="DDI-PubMed.28680834.s6.e4" /></sentence><sentence text=" Sofosbuvir and dasabuvir are NS5B inhibitors"><entity charOffset="1-11" id="DDI-PubMed.28680834.s7.e0" text="Sofosbuvir" /><entity charOffset="16-25" id="DDI-PubMed.28680834.s7.e1" text="dasabuvir" /><pair ddi="false" e1="DDI-PubMed.28680834.s7.e0" e2="DDI-PubMed.28680834.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28680834.s7.e0" e2="DDI-PubMed.28680834.s7.e1" /></sentence><sentence text=" Currently, a combination of two or more DAAs is the corner stone for the treatment of HCV infection" /><sentence text=" However, the success of DAA therapy is facing several challenges, including the potential of drug-drug interactions and resistant variance" /><sentence text=" Moreover, the shortage of relevant clinical pharmacological data and drug interaction regarding DAA is a clinical concern" /><sentence text=" The present review discusses the clinical pharmacology of DAAs with special emphasis on drug-drug interaction" /><sentence text="" /></document>